Genetic Variation Impacts Pharmacokinetics of Exemestane

This article originally appeared here.
Share this content:
Genetic Variation Impacts Pharmacokinetics of Exemestane
Genetic Variation Impacts Pharmacokinetics of Exemestane

THURSDAY, Aug. 3, 2017 (HealthDay News) -- The OATP1B1 c.521>C single nucleotide polymorphism (SNP) influences exemestane pharmacokinetics in healthy postmenopausal women, according to a study published online July 29 in the Journal of Clinical Pharmacy and Therapeutics.

B.J. Gregory, Pharm.D., from the Harding University College of Pharmacy in Searcy, Ark., and colleagues conducted a retrospective pharmacogenetic study to examine the impact of the OATP1B1 c.521T>C SNP (rs4149056) on the pharmacokinetics of exemestane in healthy volunteers. Exemestane was administered orally to 14 healthy postmenopausal women; they were all sampled for pharmacokinetic analyses and genotyped retrospectively.

The researchers found that five of the subjects were carriers of the minor C allele (OATP1B1 c.521TC+ CC) and nine were carriers of OATP1B1 c.521TT genotype. Over eight-hours post-dosing, pharmacokinetics were analyzed. The OATP1B1 genotype groups had statistically significant differences in the plasma exemestane area under the curve (AUC0-8) (P = 0.04). Statistically significant differences were also seen in the plasma AUC0-8 of 17-hydroexemestane between the OATP1B1 genotype groups (P = 0.04).

"Our data suggest that the OATP1B1 c.521T>C SNP may influence exemestane pharmacokinetics in humans," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »